China is participating in a World Health Organization-backed vaccine effort, stepping in to fill a void in global health leadership created by the Trump administration.

Beijing on Thursday joined the US$18 billion ($24.45 billion) Covax initiative that aspires to give lower-income countries the same access to vaccines as wealthier nations, the Chinese Foreign Ministry said. Details of China’s commitment, including its amount of funding, weren’t immediately disclosed.

“Even when China is leading the world with several vaccines in advanced stages of R&D and with ample production capacity, it still decided to join Covax,” spokeswoman Hua Chunying said in a statement Friday. “We are taking this concrete step to ensure equitable distribution of vaccines, especially to developing countries, and hope more capable countries will also join and support Covax.”

President Xi Jinping promised in May that vaccines developed by China would be made a global “public good” to be shared by all. In recent months, Beijing had been sending positive signals, suggesting it would take part in the Covax program, without committing outright.

The decision also could become another point of contention with the US, as tensions between the world’s two biggest economies spiral on fronts from trade to technology and human rights. The Trump administration has refused to join Covax, with a spokesman for the White House saying the US wouldn’t “be constrained by multilateral organizations influenced by the corrupt World Health Organization and China.”

China’s participation is a big win for Covax, as the possibility of providing doses to even a fraction of China’s 1.4 billion people would boost critical mass, enhancing the alliance’s negotiating power.

Covax is led by the Coalition for Epidemic Preparedness Innovations and the vaccine alliance Gavi. It currently has nine vaccines in development and nine under evaluation in its portfolio, with a goal to secure 2 billion doses by 2021.

For China, participation would provide a de facto insurance policy that allows it access to any successfully developed vaccine. Beijing could also provide manufacturing support for a successful vaccine, regardless of which country develops it.

The decision could also help the country’s image following widespread criticism from abroad over how it handled the initial outbreak in the central city of Wuhan, where Covid-19 first emerged last year. China has been a front-runner in developing vaccines against the coronavirus. Nine of China’s vaccine candidates have entered clinical trials, and four of them got approval for final stage Phase III clinical trials in foreign countries.

China joins WHO-backed virus vaccine programme

Singapore 'acutely aware' of global competition to be AI hub, plans to triple AI talent pool to 15,000

MSCI boss warns of climate risks

Keppel to acquire 50% stake in European asset manager Aermont Capital for up to $517 mil

Local banks 'resilient' in 2023, but MAS warns of deteriorating asset quality, climate transition risks

The new kings and queens of content

UOB Kay Hian and CGS-CIMB analysts stay put on IHH Healthcare

CGS-CIMB reiterates Boustead Singapore at 'add' and $1.40

Citi lowers FLCT's TP to $1.24, cuts FY2024 and FY2025 DPU estimates by 8.4%

China joins WHO-backed virus vaccine programme

Related News

Highlights

Singapore 'acutely aware' of global competition to be AI hub, plans to triple AI talent pool to 15,000

Related News

Medical supplies firm Pasture Holdings aims to raise $5 million via all-placement IPO

BioNTech beats estimates as vaccine maker pursues more diseases

Covid-19 global health emergency is over after three years: WHO